MOLECULIN BIOTECH, INC. MBRX Balance Sheet

Moleculin biotech, inc. (MBRX)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15
Assets
Current assets:
Cash and cash equivalents
11,649	10,735	15,409	18,695	8,782	7,134	8,600	11,722	13,114	7,714	8,736	9,272	8,881	5,007	6,183	7,244	259	28
Prepaid expenses and other current assets
2,138	2,749	3,177	-	-	-	760	1,170	634	-	727	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	1,507	831	840	-	-	-	588	-	809	269	215	244	315	-	0
Total current assets
13,787	13,484	18,586	20,202	9,613	7,974	9,360	12,892	13,748	8,302	9,463	10,081	9,150	5,222	6,428	7,559	-	28
Furniture and equipment, net
271	316	358	401	431	463	391	26	33	33	22	20	19	23	16	7	-	0
Intangible assets
11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,148	11,128	11,173	-	0
Operating lease right-of-use asset
266	287	306	103	106	-	-	-	-	-	-	-	-	-	-	-	-	-
Note receivable - Moleculin, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	30	-
Total assets
25,472	25,235	30,398	31,854	21,298	19,585	20,899	24,066	24,929	19,483	20,633	21,249	20,317	16,393	17,573	18,740	289	28
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
1,206	2,153	3,188	1,257	2,799	1,246	785	1,676	570	810	-	-	-	399	-	-	-	-
Accrued expenses and other current liabilities
2,029	1,417	1,111	1,390	1,251	2,452	1,825	1,839	766	902	-	-	-	650	-	-	-	-
Deferred compensation - related party
-	-	-	-	-	-	150	150	-	0	-	-	-	-	-	-	-	-
Warrant liability - current
-	-	6,820	6,944	2,386	180	369	451	463	503	-	-	-	0	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	1,089	645	858	-	944	721	363	322
Accounts payable and accrued expenses-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	37	100	-	-
Convertible notes payable
-	-	-	-	-	-	-	-	-	-	0	0	108	296	297	431	615	450
Warranty liability
-	-	-	-	-	-	-	-	-	-	743	1,185	1,238	-	-	-	-	-
Total current liabilities
3,235	3,570	11,119	9,591	6,436	3,878	3,129	4,116	1,799	2,215	1,832	1,830	2,204	1,345	1,280	-	-	772
Operating lease liability - long-term, net of current portion
248	276	304	171	180	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term deferred compensation – related party
-	-	-	-	-	-	0	0	150	150	150	150	125	88	-	-	-	0
Deferred rent - long-term
-	-	-	-	-	107	92	-	-	0	-	-	-	-	-	-	-	-
Warrant liability - long-term
6,697	5,818	0	0	0	1,328	2,710	3,202	2,410	0	-	0	1,846	-	-	-	-	-
Long-term payable-related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	-	-	-
Total liabilities
10,180	9,664	11,423	9,762	6,616	5,313	5,931	7,318	4,359	2,365	1,982	1,980	4,175	1,433	1,330	1,252	978	772
Commitments and contingencies (Note 7)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	-	0	0
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0
Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and December 31, 2019, 53,227,700 and 45,727,700 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
53	46	46	45	34	29	27	27	26	21	21	21	18	12	12	11	6	6
Subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	3	3	3
Additional paid-in capital
56,011	55,055	54,673	53,643	45,021	40,564	38,491	38,247	36,951	31,577	29,925	27,711	21,128	19,623	19,485	19,298	388	0
Accumulated other comprehensive income (loss)
-2	31	19	22	24	35	21	-	-	0	-	-	-	-	-	-	-	-
Accumulated other comprehensive income
-	-	-	-	-	-	-	6	-	-	-	-	-	-	-	-	-	-
Warrant receivable
-	-	-	-	-	-	-	-	-	-	-	34	-	-	-	-	-	-
Accumulated deficit
-40,800	-39,561	-35,800	-31,600	-30,400	-26,356	-23,571	-21,532	-16,407	-14,480	-11,295	-8,429	-5,004	-4,675	-3,251	-1,819	-1,080	-748
Total stockholders’ equity
15,292	15,571	18,975	22,092	14,682	14,272	14,968	16,748	20,570	17,118	18,651	19,269	16,142	14,960	16,243	17,487	-688	-744
Total liabilities and stockholders’ equity
25,472	25,235	30,398	31,854	21,298	19,585	20,899	24,066	24,929	19,483	20,633	21,249	20,317	16,393	17,573	18,740	289	28